Skip to main content
. 2022 Mar 16;17(3):e0264138. doi: 10.1371/journal.pone.0264138

Fig 4. Frequencies of targetable known/likely rearrangements in common tumor types detected by F1CDx between 2018 and 2020.

Fig 4

Source: from over 504,000 Foundation Medicine profiles consented for secondary research, 191,575 unique US patients tested with F1CDx from Jan. 14, 2018 through Mar. 31, 2021. CRC = colorectal cancer; NSCLC = non-small cell lung cancer.